Advertisement


Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

2025 ASCO Annual Meeting

Advertisement

Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
As a 31-year organization, this validates who we are because we have been doing the work for all these years. But this particular national or international award will now allow us to pivot and move forward quickly because it's a validation from an international oncology professional organization. We have to look back from the beginning. Shame and fear and isolation were what I found existed in the beginning. So as an organization, I knew what was missing within our community. We needed to combat the fear and the shame and empower women to be active in action in the advocacy field. Our creed is: in unity, there is strength; in strength, there is power; and in power, there is change. We are at the action/change position within our organization and in our community. What we were trying to do, and continue to do, is to let women know that breast cancer means us, and without that information, we found that the guidelines did not meet the needs of the African American community. Being diagnosed before age 40 is a reality within our community. As a national organization, we recognized that early on, and from 1995, we started telling the community that you need to get your baseline before age 40, and that was sort of unique but needed. We have continued to do that. Now that we're in the action phase of our organization, we're going to work towards lowering the guidelines to meet the reality of our community. Sisters Network—we are focused on our BCAP program, which is Breast Cancer Assistance. Since 1996, we have been providing financial assistance for mammograms for underserved women and also for rent or utilities after diagnosis. We are in a position of helping women get over that hump so they can go back to work or return to real life, and their journey is that much easier. One of the things our organization provides—because we definitely believe in sisterhood—is emotional support, helping you understand that you are not alone and that you are supported by an organization that has a national vision. I have to believe that doctors have a major role in the forward motion of the guidelines and in women getting the services they need at the time they need it. For instance, if you come to a doctor and you're 35 and you know there's something going on in your breast and you want to get some tests, but you're not old enough, I would hope that doctors at this point will refer you to organizations that can help you navigate the system so you can get what you need.

Related Videos

Colorectal Cancer

Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial

Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encorafenib, cetuximab, and mFOLFOX6 in BRAF V600E–mutant metastatic colorectal cancer (LBA3500). 

Prostate Cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer (SCLC) (Abstract 8006).

Lung Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009). 

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). 

 

Advertisement

Advertisement




Advertisement